MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting
Rights
ROCKVILLE, MD, January 2,
2025: MaxCyte Inc., (NASDAQ:
MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery,
development, and commercialization of next-generation cell
therapeutics and to support innovative, cell-based
research, announces that pursuant to its block admission
facility, since 30 November 2024 it has issued 19,904 of
common stock, $0.01 par, of the Company ("Common Stock") in
satisfaction of the exercise of share options and/or vesting of
restricted stock units.
Total voting rights
As at 31 December 2024, the total
issued stock capital of the Company following the recent issue of
the new Common Stock is 105,711,093 shares of Common Stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
For further information, please
contact:
|
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
|
|
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients'
lives. We have spent more than 25 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to
innovate tomorrow's solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation® technology, has been designed
to support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and
follow us on X and LinkedIn.